六人,包括四名巴基斯坦男子,在41M内幕交易计划内,使用假药物数据和合并秘密来操纵药剂库存,收取41M内幕交易费。 Six people, including four Pakistani men, charged in $41M insider trading scheme using fake drug data and merger secrets to manipulate pharma stocks.

6人,包括4名巴基斯坦籍男子,在一项4 100万美元的内幕交易和市场操纵计划中受到指控,针对的是发展癌症和阿片类药物过量治疗的制药公司。 Six people, including four men of Pakistani origin, have been charged in a $41 million insider trading and market manipulation scheme targeting pharmaceutical companies developing cancer and opioid overdose treatments. 该欺诈活动从2020年至2024年活跃,涉及盗窃的非公共信息、伪造的临床数据和假新闻稿,以抬高股票价格。 The fraud, active from 2020 to 2024, involved stolen non-public information, falsified clinical data, and fake press releases to inflate stock prices. 检察官指控,该集团通过秘密合并细节交易和伪造毒品试验结果,包括一家公司库存激增近30%,获得了非法利润。 Prosecutors allege the group generated illicit profits by trading on confidential merger details and fabricating drug trial results, including a nearly 30% stock surge for one company. 被告面临多项联邦指控,可能被判处最高25年的监禁。 The defendants face multiple federal charges with potential prison sentences of up to 25 years.